Article
Recently launched trial investigates anecortave acetate for preventing AMD progression to exudative disease
Enrollment has recently begun in the anecortave acetate risk reduction(AART) study that is designed to evaluate the efficacy of that angiostaticsteroid for reducing the risk of progression from dry to exudative age-relatedmacular degeneration (AMD), said Jason S. Slakter, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
